Introduction
Since 2011, the number of people diagnosed with diabetes mellitus (DM) in the UK has increased from 2.9 million to 3.2 million [1] . Management of type 2 diabetes mellitus (T2DM) often requires pharmacologic intervention with therapies given via the oral route. However, due to the progressive nature of the condition, patients may also require initiation of injectable therapies to improve glycaemic control. Current injectable therapies include use of insulin (basal, fast acting or pre-mixed) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
Unlike oral therapies, injectable therapies often require additional time and resources during the initiation period.
Depending on local protocols, initiation of injectable therapies may be undertaken in primary, intermediate or secondary care. In the UK, real-world evidence on best practice in initiation of injectable therapies, the associated healthcare costs and its impact on patient experience is lacking.
The rationale for using injectable therapies in T2DM management has been described at a national level. In 2009, the National Institute for Health and Care Excellence (NICE) issued guidance on the management of T2DM in England [2] . Guidance around T2DM management recommends initial therapy with metformin in obese or overweight patients. Metformin should be continued if control of blood glucose remains or becomes inadequate, with addition of another oral glucose-lowering Drugs in Context 2015; 4: 212269 ORIGINAL RESEARCH -Resource use and outcomes associated with initiation of injectable therapies for T2DM Drugs in Context medication (e.g., sulfonylurea, dipeptidyl peptidase-4 inhibitors, thiazolidinediones) added to the treatment. Guidance also highlights the importance of achieving and maintaining a target level of HbA 1c . It recommends use of a GLP-1 RA if control of blood glucose remains or becomes inadequate and the person has a high body mass index (BMI) of ≥35 kg/m 2 [1] and problems associated with high body weight, or if the BMI is <35 kg/m 2 and losing weight would help other weight-related health problems, or if taking insulin would greatly affect his/her ability to work. GLP-1 RAs act in a glucose-dependent manner to improve glycaemic control and reduce weight, with a low risk of hypoglycaemia [3] . Use of insulin therapy is recommended if control of blood glucose remains or becomes inadequate with other measures, albeit with a known risk of hypoglycaemia and weight gain [4] .
Similar guidelines to those provided by NICE include those presented by the American Diabetes Association (ADA) [5] and American Association of Clinical Endocrinologists (AACE) [6] . ADA guidelines recommend the following pharmacologic therapies for hyperglycaemia in T2DM: metformin as the initial pharmacologic agent; insulin therapy with or without additional agents in newly diagnosed T2DM patients with markedly symptomatic and/or elevated blood glucose levels or HbA 1c ; addition of a second oral agent (GLP-1 RA or insulin) if non-insulin monotherapy at the maximum tolerated dose does not achieve or maintain the HbA 1c target over 3 months.
Guidance also suggests that a patient-centred approach should be used to guide choice of pharmacologic agents and that, due to the progressive nature of T2DM, insulin therapy is eventually indicated for many patients.
Similarly, AACE guidelines for glycaemic control recommend that, to start, the baseline level of HbA 1c is selected. If it is: <7.5%, then monotherapy should be given; ≥7.5%, then dual therapy should be given; >9.0% with no symptoms, then triple therapy should be considered; >9.0% with symptoms, then insulin with other agents should be given.
DM management has a considerable impact on use of healthcare resources and is a high priority for the National Health Service (NHS) [7] . In 2012, it was estimated that ≈10% of the NHS budget was spent on DM management alone, which equates to £9.8 billion in direct costs in 2010/11 with £8.8 billion of the cost derived from T2DM patients [8] . Around 80% of this budget was spent on complications related to disease, including cardiovascular disease and hypoglycaemia [8] . A few studies have explored the cost of T2DM [8, 9] and the healthcare resource use associated with basal insulin [10, 11] . However, none have evaluated the time and costs of NHS staff associated with initiating and supporting therapy using basal insulin and GLP-1 RAs in a UK setting.
Across NHS England, the setting for initiating injectable therapies may occur in secondary, intermediate or primary care. The cost and resource use associated with this service may vary due to the complexity of the initiation (particularly for basal insulin in terms of dose titration) and the level of staff involvement (e.g. for the education and support of patients) which (at least in part) may influence the cost of the service per patient. Therefore, in accordance with the 2014/2015 NHS Mandate (between the government and NHS England) [12] to ensure good financial management and unprecedented improvements in value for money across the NHS (as specified in point 8), it is important to consider all relevant costs to gather complete understanding of the overall use of resources in each of these settings. Such information could be used to inform the delivery of diabetes care services.
Making better use of resources and addressing clinical goals are key to DM management. However, positive experiences by patients and involvement in decisionmaking have also been highlighted as important factors, particularly during initiation of injectable therapy [13, 14] . The prominence of the patient experience has also been raised in commissioning standards [15] and the NHS Outcomes Framework (domain 4) [16] . The recent policy drive to bring care of long-term conditions closer to patients has led to diversification of service models for DM in the NHS so that injectable therapies may be initiated across different care settings. However, it is unclear how patients' experiences of injectable therapies for DM vary across these settings.
Therefore, using tariff cost and micro-costing analyses, the aim of this series of service evaluations was to understand: current resource utilisation and costs by NHS staff associated with initiating injectable therapies for T2DM; the pathways of care; clinical outcomes and patient experiences in primary, secondary and intermediate care and how this may differ for insulin and GLP-1 RA therapies.
Methods
We conducted three service evaluations of initiation of injectable therapies for T2DM (one each in primary, secondary and intermediate care) using three methods of evaluation for each service. These evaluations were: a retrospective cohort review of medical records and service administration systems; a prospectively self-reported evaluation of NHS staff time on each episode of patient contact during the initiation period; a survey of patients attending for initiation of injectable therapy for DM. There was no change to the care of patients for any part of these evaluations.
Centre description
Whitstable is a primary care medical practice with ≈1,600 patients with T2DM led by a clinician and two diabetes nurse specialists. Both nurses have training in DM management and one is an independent nurse prescriber. Patient data are captured electronically using the EMIS database from the Egton Medical Information Systems Group [17] . Questionnaire on patient experiences
Patients were eligible to take part in completing questionnaires on patient experiences if they: were aged ≥18 years at the time of initiation of GLP-1 RA or basal insulin; had a diagnosis of T2DM initiated on GLP-1 RA or basal insulin; were attending clinic during a specified 2-month period (at any point during the 3-month initiation phase); consented to complete a patient questionnaire. Patients who had been initiated with a GLP-1 RA or basal insulin were excluded. Patients who attended clinics were identified and checked for eligibility by clinic staff by cross-referencing the date of initiation of a GLP-1 RA/basal insulin with their date of birth. Eligible patients were approached by clinic staff who explained the study to them, provided them with written information, and sought their consent to participate.
Data regarding patient experiences of the service were collected using a specifically designed questionnaire for patient self-reporting. Participating patients were provided with a questionnaire to complete during their attendance or at home according to their preference, and a pre-paid envelope was provided for return of the questionnaire. If returned patient questionnaires contained missing or obviously incorrect data, these data were treated as "missing" and the patient was not contacted to resolve queries.
Data analyses
Data from each service evaluation were analysed separately.
There was no pooling of data because it was intended only for local use in each setting. Feasibility work suggested that commonly patients would attend a three-month follow-up visit after initiation of basal insulin or a GLP-1 RA which would be a readily identifiable event. It was anticipated that "post-initiation" data would be collected at that visit. Once data collection was underway, it was apparent that this was not necessarily the case. "End of initiation" review appointments were not necessarily identifiable from medical records. Hence, those records were reviewed for ≤5 months after the index date (the index date is considered to be the date that treatment was initiated) for HbA 1c and 6 months after the index date for weight and the BMI. Similarly, not all the required baseline data were available at the date of initiation (index date), so records were reviewed for ≤2 months before the index date for HbA 1c and ≤3 months before or 7 days after the index date for weight and the BMI.
No explicit consent was sought from patients to use their medical records for service evaluations. Under UK regulations, such consent was not required at the time evaluations were conducted because service evaluations were treated as a necessary part of good quality care and hence included in the Drugs in Context 2015; 4: 212269 ORIGINAL RESEARCH -Resource use and outcomes associated with initiation of injectable therapies for T2DM Drugs in Context
Results

Retrospective review
A total of 133 patients were included across all settings. Patients were included if they were considered to require initiation of injectable therapy. Fifty patients were included from each of the primary and intermediate care settings; 23 (46%) and 29 (58%), respectively, were initiations for basal insulin. Thirty-three patients were included from secondary care, of which 2 (6%) were initiations for basal insulin. There were fewer initiations for basal insulin assessed in secondary care due to the difficulty in identification of patients initiated on basal insulin, primarily due to local prescribing protocols and because patients may have been prescribed GLP-1 beforehand.
Demographics
Patient age ranged from 31 years to 85 years. The mean (SD) age for patients initiated on basal insulin was 51.0 (9.9) years for secondary care, 60. [19] . These rates were applied to the mean time per episode as selfreported by NHS staff to calculate a mean cost per visit type. The 2013 edition of this publication did not include an hourly rate for consultant time, but instead an overall contracted hours rate (£139). However, the 2010 edition of this publication [20] provides an estimate of 69% of consultant time as direct patient contact. This weighting was applied to the contracted hours rate to give an hourly rate for direct patient contact time of £201.
Mean costs per episode were applied to the mean number of each episode of care (initiation visits, follow-up visit, and follow-up telephone call) per 3-month period to calculate a mean per patient cost of resource use during the full 3-month initiation period. If data were missing for the staff time evaluation used, for example, for telephone follow-up call times for basal insulin initiations in all settings and GLP-1 RA initiations in primary care, no costs were applied to this resource use.
HCPs and Agenda for Change (AfC) banding
HCPs involved in initiation and follow-up visits included consultant physicians, practice nurses, and nurses with NHS banding 5, 6 and 7 as defined by the current AfC grading and pay system for all NHS staff [21] . The AfC job-evaluation system determines a point score that is used to match jobs to one of the nine pay bands. A fully qualified nurse would start at band 5.
NHS tariff cost analyses
For intermediate and secondary care, the relevant national cost for initiation was derived from the 2014/15 outpatient tariff for Diabetic Medicine [22] . This is a cost for an appointment in a consultant-led clinic in an outpatient setting (usually in an acute hospital). There may be locally agreed intermediate care tariffs, however, in the absence of published evidence on the tariff cost in intermediate care. The same cost was applied to an initiation in an intermediate care setting [23] , which is likely to overestimate the true costs of this service.
For each patient, tariff costs were applied to initiations. NHS staff time during the initiation phase
In primary care, the initiation visit was reported as 30 min and the follow-up visit as 15 min. Two episodes of care were evaluated and a diabetes practice nurse managed the consultation (Table 3) .
In intermediate care, the initiation visit was reported to range from 55 min to 60 min. Follow-up initiation visit was reported to be 60 min for basal insulin and 30 min for GLP-1
For patients initiated on a GLP-1 RA, the most common side effect was nausea/vomiting/diarrhoea affecting 5 (16%) secondary-care patients, 7 (33%) intermediate-care patients, and 6 (22%) primary-care patients. In secondary care, 1 patient discontinued treatment due to nausea and 1 patient due to a swollen face. In intermediate care, 1 patient withdrew 13 days after experiencing nausea and vomiting. None of the patients who experienced hypoglycaemia withdrew from treatment during the period of data collection.
Evaluation of NHS staff time
More patients were analysed in the retrospective data analysis, but data from the prospective evaluation of NHS staff time was received on fewer initiations than expected. Due to local prescribing protocols in primary care, it was particularly difficult to identify eligible patients for injectable initiation to estimate the NHS staff time involved in this activity for this evaluation.
Time to referral
Patients had median (interquartile range (IQR)) waiting time from referral to initiation of basal insulin of 1. 
Questionnaire on patient experiences
Questionnaires were completed by 20 patients. Not all respondents provided a response to each question and, in some instances, questions were not applicable for certain patients.
There was little variation in the responses from patients in the three settings and these were, in general, positive. Respondents stated that: they found it easy to speak to a member of the diabetes team; if they had concerns they were always given the opportunity to discuss them; concerns were addressed adequately and questions answered in a way they could understand.
Discussion
The purpose of this series of service evaluations was to describe the current NHS staff resource use utilized in initiation of injectable T2DM therapies, pathways of care, clinical outcomes, and patient experiences across three care settings: primary, intermediate and secondary.
Retrospective review
This retrospective service evaluation aimed to describe the estimated number of patients that would be initiated over RAs. Activities were shared between band-5, band-6 and band-7 nurses.
In secondary care, initiation visits were associated with ≈50 min of direct care time involving 20 min with the consultant and 30 min with the band-7 nurse. Follow-up visits ranged from 35 min to 50 min and a time per telephone follow-up call of 5-15 min. Initiation visit involved a consultant physician and a band-7 nurse, with all follow-up activity undertaken by a band-7 nurse.
NHS staff resources during the initiation period
In primary care, estimated costs for GLP-1 RA were £26.00 for an initiation visit and £13.00 for a follow-up visit ( Three months after initiation with GLP-1 RA, 55% in primary care, 25% in intermediate care, and 42% of patients in secondary care saw a weight reduction of ≥3%. These results reflect findings from a nationwide audit of liraglutide use that showed an average weight loss of -3.1 kg at 3 months [25] . Unexpectedly, 1 patient initiated on basal insulin had a weight reduction of ≥3%. However, for most of the patients initiated on basal insulin, average weight increased in all three settings. Basal insulin is anabolic in nature, so this is an expected outcome and consistent with other evidence that has shown weight gain after initiation of basal insulin [25, 26] .
Similarly, the baseline BMI was higher for patients taking GLP-1 RA than those on basal insulin. NICE recommends that GLP-1 RA should be considered if the BMI is ≥35 kg/m 2 and patients do not have glycaemic control [2] . This strategy suggests that NICE guidance is being considered when initiating a patient on a GLP-1 RA in all settings. After GLP-1 RA, the mean reduction in the BMI was lower in secondary, intermediate and primary (-1.7 and -0.7 vs. -2.4 kg/m 2 ) settings. Analyses of the proportion of patients who experienced a reduction in the BMI showed that approximately one-third of patients initiated on basal insulin and at least two-thirds of those initiated on GLP-1 RA had this benefit.
Patients on basal insulin were more likely to experience hypoglycaemia during their first 3 months of treatment than patients on GLP-1 RA. However, the number of other adverse events experienced during the first 3 months of treatment was higher for GLP-1 RA patients, and included nausea/vomiting/ diarrhoea and gastrointestinal discomfort. These observations are consistent with findings from clinical trials which report a higher incidence of gastrointestinal-related adverse events with GLP-1 RA [27] . These findings highlight the importance of the education and support of patients for the known side effects of these therapies.
a 3-year period in each setting. Despite the relatively small numbers of patients included in the evaluation, baseline characteristics and clinical measurements for the basal insulin group were similar to those for large cohort studies [24] . Mean age of patients initiated on basal insulin was not similar across the three settings (P=0.02) with those in primary care being (on average) 7 years older than those in intermediate care; however, patients initiated on a GLP-1 RA were (on average) 5 years younger than patients initiated on basal insulin (P=0.014). This difference may be due to GLP-1 RA being a displaced therapy in the prescribing hierarchy, often being introduced to patients before the option of basal insulin therapy. Hypertension was the most commonly listed comorbidity for patients on basal insulin and GLP-1 RA therapies. Patients were taking various oral DM medications before initiation of basal insulin or GLP-1 RA, with a sulphonylurea and metformin being the most common. At initiation, the mean level of HbA 1c tended to be slightly (but not significantly) higher for patients taking basal insulin than for those taking GLP-1 RA across all settings. Overall, there was a reduction in the mean level of HbA 1c 3 months after initiation for both types of injectable therapy in all settings (basal insulin: intermediate and primary care; GLP-1RA: all settings). For those initiated on basal insulin, 60% initiated in intermediate care and 78% in primary care achieved a reduction in HbA 1c level of ≥1%. Achievement of reduction of a HbA 1c level of ≥1% (11 mmol/mol) was assessable in only 28 patients due to missing data. Due to small sample sizes, these differences were not significant.
In addition to reduction in HbA 1c level, patients on GLP-1 RA also experienced the added benefit of weight loss. Patients initiated on GLP-1 RA were (on average) heavier than those initiated on basal insulin. This weight difference at initiation may be due to the acknowledged weight-loss effect of GLP-1 RA, meaning that these therapies are used primarily in patients with higher weight, in accordance with NICE guidance [2] . 
Questionnaire on patient experiences
Fewer patients completed the questionnaire than expected. Responses in the three settings were, in general, positive, but these results should be interpreted with caution due to the low number of respondents. Future studies aiming to capture patient experiences should consider an alternative methodology for capturing feedback and achieving a higher response rate. Uptake of patient questionnaires could be better if patients were asked to complete the survey while they are visiting the centre as part of their routine care rather than taking it home to complete.
Limitations
This is a series of local-service evaluations aimed to describe initiation services in three healthcare settings. These results are examples of costs and, as such, are not designed to be statistically representative beyond the scope of the services evaluated. By its nature the sample was small and the aim was to provide a descriptive analysis: statistical analyses were not conducted. Retrospective data were derived from clinical 
Evaluation of NHS staff time
Where data were available, the mean NHS staff time required for an initiation visit was 30-60 min, with little difference in the amount of time required for initiation using GLP- 
Resource use
Using micro-costing methods, for the overall initiation period for which data regarding time taken for care episodes was available, the mean per patient cost for basal insulin and GLP-1 RA initiations was higher in secondary care than in other settings. Where data were available, the mean per patient initiation cost was lowest in primary care for GLP-1 RA patients. As noted in the evaluation of secondary care, GLP-1 RA initiations were more costly than those for basal insulin. This finding may be unexpected, particularly with existing outcomes achieved. As a result, the intermediate service has adapted its services to include greater use of remote follow-ups for patients.
Findings from this evaluation can be used as a guide for local diabetes services to evaluate their service delivery. Future research could expand upon these findings to produce generalizable results and explore outcomes over a longer term beyond the 3-month initiation period covered in this evaluation.
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records so the accuracy and completeness of evaluation data relies on the quality of clinical records. In many cases, data regarding weight, the BMI and HbA 1c level at 3-5 months postinitiation were missing, making it difficult to describe changes that had taken place over the first 3 months of treatment.
Overall, patient numbers were skewed towards more patients being initiated on GLP-1 RA rather than basal insulin at some of the centres. Unequal numbers of patients on basal insulin and GLP-1 meant that it is not possible to compare across therapy groups effectively. Low uptake of basal insulin at some centres may have been due to the choice and involvement of patients in discussions regarding the types of therapy available. Given the high prevalence of obesity of patients with T2DM, the benefits of weight loss and low incidence of hypoglycaemia are particularly appealing to some patients, and could explain this discrepancy.
Data were not available for the time from referral to initiation from secondary care because referrals are conducted by telephone (which are not documented). In addition, data from evaluation of NHS staff time were received on fewer episodes of care than expected. This phenomenon may have been due to the low number of patients that attended clinics during the evaluation period and the demanding workload of clinical staff conducting the evaluation, thereby not allowing time to adequately record data for this evaluation.
Where data regarding staff time needed for episodes of care were not available from staff evaluation (e.g., telephone follow-up calls for basal-insulin initiations in secondary care and all care episodes for basal-insulin initiations in primary care), no assumptions regarding staff time were made. Therefore, where data were available for some (but not all) aspects of the initiation period, resource use may have been underestimated and under-reported for basal insulin and GLP-1 RA. However, with the exception of basal-insulin initiations in primary care, missing data were limited to time for telephone follow-up calls. Telephone calls may not have a great impact on resource use as they are often shorter than visits in person. However, a series of telephone calls over a period of time may have a greater impact on resource use.
Conclusion
Despite the limitations acknowledged in this evaluation, retrospective data showed that basal insulin and GLP-1 RA were effective therapies in the treatment of T2DM. All three services, with both types of injectable therapies, achieved a reduction in HbA 1c level after initiation, with patterns of weight gain/loss and adverse events as expected. Adverse events and known side effects experienced by patients in evaluations highlight the need for patient support if a new medication is initiated.
Initiation of GLP-1 RA was associated with less staff time than initiation of basal insulin and this was a consistent difference across the three service settings. Primary care provided a less resource-intensive and less costly setting, driven largely by lower staff costs and fewer face-to-face clinic visits, with similar
